Searched for
DAIICHI SANKYO CO LTD
AstraZeneca, Gilead vie for edge in race to treat tough breast cancerNew data from Europe's biggest oncology meeting reveals a high-stakes race for patients with a tough breast cancer. Astra and Daiichi's Dat...- Daiichi Sankyo, Merck ink $22-billion cancer drug dealThe deal adds promising drug candidates to Merck's oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expir...
- Daiichi seeks forensic audit into Fortis-IHH transactionsDaiichi is seeking an audit of the dilution of FHL shareholding, alleged violation of undertakings and assurance by the former FHL promoter...
- Japan shares end higher as investors eye Fed policy stanceThe Nikkei 225 Index finished trade up 0.09% at 23,475.53, with the telecommunications and healthcare sectors leading gains. The broader To...
- The CEO who capped a $37 billion recovery with AstraZeneca dealNakayama decided to reboot Daiichi Sankyo, pivoting toward the more lucrative business of cancer drugs.
- This drug may replace chemotherapy, redefine cancer careThese drugs will attack cancer cells in the body without damaging surrounding healthy ones.
- Sun Pharma-Ranbaxy deal: Daichi Sankyo failed to harness the complexities of a strong generic business, says Malvinder SinghThe Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.
- Ranbaxy likely to open higher on $3.2 billion deal with Sun PharmaRanbaxy to open higher after Sun Pharma said it will buy generic drug maker in an all-share deal with total equity value of $3.2 bn.
- Ranbaxy, Daiichi to leverage on brand strength for global marketsIn a bid to strengthen their hybrid business model, Ranbaxy and its parent firm Daiichi Sankyo will project only one of them as the face of...
- Ranbaxy's $500 mn US fine: Daiichi may sue ex-promoters Malvinder, ShivinderDaiichi Sankyo was examining the option of suing the Singh brothers for reputational damage and to reclaim the $500-million penalty.
- Ranbaxy, Daiichi Sankyo to leverage synergies in ThailandRanbaxy Laboratories and its Japanese parent Daiichi Sankyo to integrate their business operations in Thailand to maximise synergies.
- Daiichi's own man to head Ranbaxy qualityJapan's Daiichi Sankyo has named an executive with more than 25 years of experience to oversee the quality and manufacturing standards in R...
- Ranbaxy to shift focus from new drug research to genericsRanbaxy Laboratories has said it is shifting the focus of its research from the development of new drugs to that of generic drugs for effec...
- Daiichi-Ranbaxy synergy plan delayed, announcement by MarRanbaxy Laboratories and its Japanese parent Daiichi Sankyo's proposal to unveil a three-year plan for exploiting synergies in operations t...
- Stocks to watch: Kingfisher Airlines, Ranbaxy, Unitech, SAIL, Patni Computers, BPCLPatni Computers’ net profit for quarter ended December rose to $40.5 million vs $35.7 million and sales grew to $ 170.2 million against $16...
- Ranbaxy to market Daiichi’s products in MexicoDaiichi Sankyo said its Indian arm Ranbaxy Laboratories will start selling its original products in Mexico as part of its strategy to lever...
- Ranbaxy Laboratories rejigs board, Malvinder is chairmanRanbaxy Laboratories and its new owner Japan’s Daiichi Sankyo on Friday reconstituted a new 10-member board.
- Ranbaxy announces reconstitution of Board of DirectorRanbaxy Laboratories and Japanese drug major Daiichi Sankyo today jointly announced the reconstitution of the Gurgaon-based company's Board...
- Daiichi Sankyo acquires 52.5% stake of RanbaxyThe board of directors at Ranbaxy Laboratories approved the allotment of equity shares and warrants on a preferential basis to Daiichi Sank...
- Experts call Ranbaxy sell off as good dealThe deal in which Ranbaxy Laboratories Ltd India's largest pharmaceutical company was sold off to a Japanese-based Daiichi Sankyo Co has be...
Load More
